

CV Date	19/12/2025
----------------	------------

Part A. PERSONAL INFORMATION

First Name *	Jorge		
Family Name *	Bartolomé Arcilla		
Sex *	Male	Date of Birth *	10/05/1991
ID number Social Security, Passport *	05440199D	Phone Number *	
URL Web			
Email Address	jorge.bartolome@salud.madrid.org		
Researcher's identification number	Open Researcher and Contributor ID (ORCID) *	0000-0002-2715-6529	
	Researcher ID		
	Scopus Author ID		

* Mandatory

A.1. Current position

Job Title	Clinical Head of Experimental Therapeutics in Cancer Unit (Early Phase Clinical Trials Unit)		
Starting date	2024		
Institution	Hospital Clínico San Carlos		
Department / Centre			
Country		Phone Number	
Keywords			

A.2. Previous positions

Period	Job Title / Name of Employer / Country
2016 - 2021	Medical Oncology Resident / Hospital Clínico San Carlos

A.3. Education

Degree/Master/PhD	University / Country	Year
Master in Molecular Oncology	Universidad Rey Juan Carlos	2025
Master in Medical Oncology: SEOM Certificate	Institut Català d'Oncologia	2021
Master in Clinical Medicine	Universidad Camilo José Cela	2016
Medicine Degree	Universidad Autónoma de Madrid	2015

Part B. CV SUMMARY

Jorge Bartolomé graduated in Medicine at the Universidad Autónoma de Madrid in 2015 and, subsequently, specialized in Medical Oncology at the Hospital Clínico San Carlos San Carlos in Madrid between 2016 and 2021. During that period he completed his training with a master's degree in Clinical Medicine and the master's degree of the Spanish Society of Medical Oncology (in Spanish, SEOM). In the last year of the specialty, he is trained for 3 months at the Vall d'Hebron Hospital in Barcelona, gaining experience in a reference unit for clinical trials in early development (phase I and early phase II trials).

After completing his residency and becoming a specialist, he contributed in the creation and subsequent accreditation of the Experimental Therapeutics in Cancer Unit (in Spanish, UTEC) of the Hospital Clínico San Carlos, specialized in clinical trials in early phases, where he has been working as medical oncologist since June 2021 and he is an investigator in more than 20 phase I and phase II clinical trials. His scope of work includes all tumor types, but he is specialized in immunotherapy, molecular medicine and precision oncology, launching and

coordinating the Molecular Tumor Board of the Hospital Clínico San Carlos. Since March 2024, he is in charge of the clinical area of the Experimental Therapeutics in Cancer Unit.

He also develops his research activity within the Clinical and Translational Research in Oncology Group led by Dr. Pérez Segura and in the Experimental Therapeutics Laboratory led by Dr. Ocaña. He currently has several publications and multiple communications at conferences and congresses, both nationally and internationally.

He is a member of various scientific societies, such as SEOM, GETTHI or ESMO. In addition, since 2023 he has been an advisor to the Drug Research Ethics Committee of the Hospital Clínico San Carlos and a teaching collaborator at the Universidad Complutense de Madrid, as well as other entities.

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Publications

AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

- 1 Scientific paper.** Benítez-Fuentes J.; (2/11) Bartolomé J.; Lázaro A.; et al; Ocaña A.2025. Association between Human Leukocyte Antigen E Expression and Outcomes in Solid Tumors: a Systematic Review and Meta-analysis. *Frontiers in Oncology*.
- 2 Scientific paper.** Nieto-Jimenez C.; Garcia-Lorenzo E.; Diaz-Tejeiro C.; et al; Ocaña A.; (9/16) Bartolomé J.2025. In silico evaluation of the immunogenic profile of lung cancers with SMARCA4 genetic alterations. *Scientific Reports*.
- 3 Scientific paper.** Piha-Paul SA; Call JA; Spira AI; (4/8) Bartolomé J; de Miguel M; Chen X; Donatelli SS; Lakhani NJ. 2025. Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trial. *The Oncologist*.
- 4 Scientific paper.** 2024. Durable benefit and slowdown in tumor growth dynamics with erdafitinib in a FGFR3-TACC3 fusion-positive IDH-wild type glioblastoma. *Neuro-Oncology Advances*.
- 5 Scientific paper.** 2024. Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2. *International Journal of Molecular Sciences*.
- 6 Scientific paper.** Paniagua-Herranz L; Díaz-Tejeiro C; Sanvicente A; (4/6) Bartolomé J; Nieto-Jimenez C; Ocaña A. 2024. Overcoming limitations for antibody-based therapies targeting $\gamma\delta$ T (Vg9Vd2) cells. *Frontiers in immunology*.
- 7 Scientific paper.** Benitez Guentes JD; (2/11) Bartolomé Arcilla J.; Mohamed Mohamed K.; et al; Sanchez-Ramon S.2024. Targeting of Non-Classical Human Leukocyte Antigens as Novel Therapeutic Strategies in Cancer. *Cancers*.
- 8 Scientific paper.** 2024. Understanding the Preclinical Efficacy of Antibody–Drug Conjugates. *International Journal of Molecular Sciences*.
- 9 Scientific paper.** Escudero A; (2/2) Bartolomé J (AC). 2023. Bases de las combinaciones farmacológicas en oncología. *Actualidad en Farmacología y Terapéutica*. 21-2, pp.101-106.
- 10 Scientific paper.** (1/2) Bartolomé J (AC); et al. 2023. Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis. *Frontiers in immunology*.
- 11 Scientific paper.** 2022. Adverse drug reactions to the three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) mRNA-1273 vaccine in a cohort of cancer patients under active treatment of a tertiary hospital in Madrid, Spain. *F1000Research*. 11, pp.434.

- 12 **Scientific paper.** 2022. Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients. *Frontiers in Oncology*.
- 13 **Scientific paper.** 2020. A snapshot of COVID-19 infection in patients with solid tumors. *International Journal of Cancer*. 148, pp.2389-2397.
- 14 **Scientific paper.** (1/2) Bartolome, J. (AC); et al. 2016. Peristomal cellulitis due to *Magnusiomyces capitatus* in a woman carrying percutaneous gastrostomy tube. *Revista Española de Quimioterapia*. 30, pp.59-61.
- 15 **Book chapter.** Jorge Bartolome; Alicia de Luna. 2024. Capítulo 14: Terapias dirigidas IV. *ONCOMECUM 2024 9ª edición*.
- 16 **Book chapter.** (1/1) Bartolome J. 2023. Cambio de oportunidades terapéuticas tras adecuado tratamiento del síndrome de anorexia-caquexia en paciente con cáncer de páncreas. *Experiencia con Acetato de Megestrol en el tratamiento del SAC en paciente oncológico*. YOU & US S.A.. ISBN 978-84-127058-0-5.
- 17 **Book chapter.** (1/2) Bartolome J; et al. 2018. Encefalopatía por ifosfamida: a propósito de un caso. *Actualizaciones temáticas en oncología*. Editorial Glosa S. L.. 2. ISBN 978-84-7429-684-6.
- 18 **Bibliographic review.** Díaz-Rubio, E.; (2/2) et al (AC). 2020. Biopsia líquida en cáncer colorrectal. *Plataforma digital ONCOMEDIC*.

C.2. Conferences and meetings

- 1 Jhaveri K.; Juric D.; Giordano A.; et al; Montero AJ.. A phase 1/2 trial of LY4064809 (STX-478), a pan-mutant-selective PI3K α inhibitor in HR+, HER2- advanced breast cancer (ABC): Updated results from PIKALO-1. *SABCS*. 2025. Participatory - poster.
- 2 Tejerina J.; et al.. Cruelty-free review of non-animal melanoma models.. VIII Reunión Traslacional 2025 del GEM (Grupo Español de Melanoma). 2025. Participatory - poster.
- 3 Amann-Arévalo M.; Garijo MC.; Moreno-Perez I.; Manzano A.; Pérez-Segura P.; De la Macorra J.; Bartolome J.. Exploring the clinical and therapeutic implications of non-hotspot mutations in POLE. *ESMO TAT*. 2025. Participatory - poster.
- 4 García Gómez M.; Antoñanzas M.; Ocaña A.; et al; Bartolomé J.. Integrated profiling of tumor antigens and immune genes in Non Small Cell Lung Cancer: Toward rational antibody-drug conjugate combinations. *ESMO Congress*. 2025.
- 5 García-Gómez M.; et al. Integrative Analysis of Tumor Antigens and Immune Genes in Cervical Cancer: A Path to Optimized ADC Combinations. *ESMO Gynaecological Cancers*. 2025. Participatory - poster.
- 6 González Díez B.; García Gómez M.; Gómez Raposo C.; Amann Arévalo M.; Moreno I.; Pérez Segura P.; Bartolomé J.. Integrative Transcriptomic Profiling of Tumor Antigens and Immune Genes in Ovarian Cancer for Rational ADC and CPI Combinations. *ESMO Immuno-Oncology*. 2025. Participatory - poster.
- 7 Cabello A.; Amann M.; García Paredes B.; et al; Bartolomé J.. Integrative Transcriptomic Profiling of Tumor Antigens and Immune Genes in Pancreatic Cancer for Rational ADC Design. *ESMO Immuno-Oncology*. 2025. Participatory - poster.
- 8 Amann-Arévalo M.; Moreno-Pérez I.; González-Díez B.; Escudero A.; Pérez-Segura P.; Ocaña A.; Bartolome J.. Next-Generation Sequencing and Liquid Biopsy: Overcoming Tissue Limitations in Oncology. *ESMO TAT*. 2025. Participatory - poster.
- 9 Yamamoto N; et al. Efficacy and Safety of Brigimadlin, a MDM2-p53 Antagonist, in Patients with Advanced Lung Adenocarcinoma. *WCLC Congress*. 2024. Participatory - poster. Conference.
- 10 Piha-Paul S; Call J; Spira A; et al; Lahkhani N. Recommended Phase 2 Dose (RP2D) of Nemvaleukin Alfa in Patients With Advanced Solid Tumors Treated With Less Frequent Intravenous Dosing (ARTISTRY-3). *ASCO Congress*. 2024. Participatory - poster. Conference.
- 11 Wysocki P; et al. Trastuzumab deruxtecan in patients with HER2-expressing bladder cancer: outcomes from DESTINY-PanTumor02. *ASCO Congress*. 2024. Participatory - poster. Conference.
- 12 Montero A; et al. First-in-human results of STX-478, a mutant-selective PI3K α inhibitor, in advanced solid tumor patients.. *ESMO Congress*. 2024. Participatory - oral communication.

- 13 Garijo M; Amman M; Manzano A; et al; Bartolomé J. Homologous recombination pathway in sarcomas: a novel opportunity of therapy?. ESMO Congress. 2024.
- 14 Muñoz-Langa J.; Quindos M.; Gálvez Montosa F.; et al; et al.. Phase II Study to assess the efficacy of niraparib rechallenge treatment after complete secondary cytoreduction in ovarian cancer patients with oligometastatic progression: the ANALLISA study. IGCS. 2024. Participatory - poster.
- 15 Sarah Donatelli; et al. Tumor Microenvironment Pharmacodynamic Effect of Nemvaleukin Less Frequent Intravenous Dosing in Multiple Solid Tumors: Results From the Phase 1/2 ARTISTRY-3 Study. SITC 2024. 2024. Participatory - poster.
- 16 Julia Tejerina-Peces; Maria Antonia Cubero; Jorge Bartolome; et al; Helena Huertas. Análisis retrospectivo del uso de catéteres centrales de inserción periférica en el servicio de Oncología Médica de un hospital terciario de España.. SEOM. 2023. Participatory - poster. Conference.
- 17 Julia Tejerina-Peces; Jorge Bartolome; Miguel De la Hoya; et al; Aranzazu Manzano. Clinical features and genetic profile of MDM2 altered tumors.. ESMO TAT. 2023. Participatory - poster. Conference.
- 18 Jorge Bartolome; Cristina Nieto; Alfonso Lopez de Sa; et al; Alberto Ocaña. Evaluation of the transcriptomic presence of tumor associated antigens (TAAs) from antibody drug conjugates (ADCs) and PD-L1 in melanoma: options for new clinical opportunities Publication category: Melanoma and other skin tumours.. ESMO Congress. 2023. Participatory - poster. Conference.
- 19 Cristina Saiz-Ladera; Jorge Bartolome; Aranzazu Manzano; Guillermo Velasco; Santiago Cabezas; Pedro Perez-Segura; Alberto Ocaña. In silico evaluation of the mutational profile of Glioblastomas with high expression of PD1, CTLA4 and LAG3 identifies the ERBB-PI3K pathway as a druggable vulnerability target.. ESMO Congress. 2023. Participatory - poster. Conference.
- 20 Gonzalo Fernandez-Hinojal; Monica Antoñanzas-Basa; Carlos Aguado-De la Rosa; Alfonso Lopez de Sa; Jorge Bartolome; et al. Clinical profile of SMARCA4/SMARCB1-altered Non-Small Cell Lung Carcinomas: a retrospective study in a Spanish institution. European Lung Cancer Congress. 2022. Participatory - poster. Conference.
- 21 Jorge Bartolome; Gonzalo Gonzalez-Hinojal; Aranzazu Manzano; et al; Pedro Perez-Segura. SMARCA4/SMARCB1 alterations detected through tissue comprehensive genomic profiling (CGP) A single-center study of prevalence and clinical characteristics.. ESMO Congress. 2022. Participatory - poster. Conference.
- 22 Jorge Bartolomé. Aplicabilidad de los biomarcadores en la respuesta a la IO. II Simposio de Medicina de Precisión en Cáncer de Cabeza y Cuello. 2021. Participatory - oral communication. Conference.
- 23 Jorge Bartolome; et al. Estudio ONCOVID: Seroconversión y respuesta inmunitaria en pacientes oncológicos tras infección por SARS-CoV-2.. SEOM. 2020. Participatory - poster. Conference.
- 24 Jesus Fuentes; Jorge Bartolome; et al. Influencia del genotipo de antígenos leucocitarios humanos en la evolución clínica, microbiológica y serológica de COVID-19 en pacientes oncológicos. SEOM. 2020. Participatory - poster. Conference.
- 25 Jorge Bartolome. Monitorización de la respuesta al bloqueo androgénico en carcinoma ductal salivar.. I Simposio de Medicina de Precisión en Cáncer de Cabeza y Cuello. 2020. Participatory - oral communication. Conference.